Expectation of Indian Pharmaceuticals and Health Science Industry
After witnessing a neutral budget last year, the Indian pharmaceutical industry has prepared itself again with its wish list for Budget 2010.
Pharma cos hope R and D sops will boost investment
Indian drugmakers could see excise duty on drugs restored to 8 percent from the present 4 percent, but they are hopeful research & development could attract some tax sops in the Union budget on Feb. 26.
Elder Pharma opens drugmaking unit in Uttrakhand
Elder Phamaceuticals said on Wednesday its new drug manufacturing facility near Dehradun in Uttarakhand state has become operational.
India still not lucrative for innovator drugs
India might be shining for multinational drugmakers, but when it actually comes to introducing innovator drugs the $20 billion Indian pharma market is light years away.
Entry of Global Pharma in generics to put strain on Indian cos
The entry of global pharma firms in the generic market will put strain on Indian drug companies, which will have to manage costs and maintain profitability to be able to compete with them, says credit rating agency Fitch.
Excise removal can trigger Rs 5k crore pharma investment
Gujarat could attract fresh investment worth Rs 5,000 crore in the pharmaceuticals sector, if the excise on pharma products, currently 4 per cent, was removed, the Gujarat wing of the Indian Drug Manufacturers' Association (IDMA) believes.
Opportunities galore in nanotechnology: IISER Director
A five-day winter school on “Nanotechnology in Advance Drug Delivery” was opened at the National Institute of Pharmaceutical Education and Research (NIPER) in Mohali on Monday. Prof N Sathyamurthy, Director, Indian Institute of Science Education and Research (IISER), Mohali, inaugurated the third winter school.
Soon, Cancer drugs at half-price from govt outlets
In a first-ever initiative to bring down prices of expensive cancer medication, the government plans to retail them through its ‘Jan Aushadhi’ stores, which offer essential ‘unbranded’ drugs at discounted rates. It has already initiated talks with domestic pharma companies to procure cancer drugs.
Cipla retains top slot in domestic pharma market
Drug company Cipla maintained its top position in the domestic market for the 12 months ended December, 2009, with a market share of 5.38 per cent — up 18 per cent over the year and ahead of Ranbaxy Laboratories and GlaxoSmithKline (GSK).
Approach patents body first: HC to pharma firms
Delhi High Court dismisses six petitions of drug majors.
Birla Kerala Vaidyashala to tie up with pharma cos for distrubtion
Birla Kerala Vaidyashala, a part of the Rs 3,000-crore Yash Birla group, intends to tie-up with local pharma companies to sell its range of products across the country, a top company official said.
Pfizer India, Arpana USAID Expand Public Private Partnership to Strengthen Healthcare Systems and
Pfizer India and Arpana Research and Charities Trust announced today the expansion of their existing grassroots initiatives aimed at strengthening the healthcare system to cover 100 low-income villages in Haryana by 2012. They also announced the launch of a joint project with USAID and CAP Foundation aimed at employment generation for rural youth.
Govt plans Rs 2,000 crore fund for pharma research
In an ambitious move to boost drug discovery, the Centre plans to create a fund of Rs 2,000-3,000 crore for pharma research and development, a top government official said here today.
No place like home, finds Indian pharma
In a recent reversal, operations abroad are hampering profit.
Indian SMEs keep pharma prices under check: Study
A global study by Health Action International, a non-government body, on the price variations of Ciproflaxin, a commonly used medicine in 93 countries, found the price charged by Bayer, the originator of the drug, to be the lowest in India.
Troikaa Pharma to get US patent for its Dyanapar AQ
Troikaa Pharmaceuticals, a Gujarat based fast growing healthcare company, is likely to get US patent for its novel drug delivery form of Diclofenac injections-Dyanapar AQ.
Dishman pharmas’ Naroda facility gets USFDA nod
Dishman Pharmaceuticals & Chemicals Ltd, a contract research & manufacturing services (CRAM) major, received the US Food and Drug Administration (USFDA) nod for producing Active Pharmaceutical Ingredients (API) at its Naroda facility here.
Innovation is the key to pharma sector future
The collapse of the property market has left the economy with a huge hole that will be difficult to fill. One of the few sectors that offers hope of growth is the pharmaceutical industry, with senior executives convinced that genuine opportunities remain for Ireland Inc.
Alliance Pharma Gains 18 New Prescription Products in Acquisition
Alliance Pharma (AIM: APH) said it has agreed a significantly earnings enhancing acquisition, buying a portfolio of 18 prescription products. The company has conditionally agreed to acquire certain assets of privately owned Cambridge Laboratories in a deal worth between £14.3m and £16.4m, plus an additional £1.4m for Cambridge’s product inventory.
Blow to Cadila’s H1N1 vaccine plan
Cadila Pharmaceuticals’ plan to indigenously develop Influenza A HINI (swine flu) vaccine in collaboration with US-based Novavax is likely to be delayed as the government has shown caution in giving go-ahead for the clinical trials.